The KRAS G12C inhibitor field is evolving at a breakneck pace. While sotorasib set an initial benchmark response rate of ~30% (in combo), newer agents like oloramoracep are already demonstrating response rates exceeding 45%, rapidly resetting efficacy expectations and treatment standards for this population.

Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

The next therapeutic frontier for RAS-mutated cancers involves combining multi-selective RAS inhibitors (e.g., daraxonrasib) with mutation-specific inhibitors (e.g., zoldon-rasib). This dual-pronged strategy aims to achieve deeper and more durable pathway inhibition by attacking the target through different mechanisms simultaneously.

Broad-spectrum RAS-on inhibitors like daraxonrasib present skin toxicity as a dose-limiting side effect. However, this rash is clinically distinct from that caused by EGFR inhibitors. It is often manageable with brief treatment interruptions, frequently without requiring dose reductions, and patients tend to acclimate to it over time.

While better tolerated than chemotherapy, daraxon-rasib's unique toxicity profile (rash, stomatitis) requires a clinical management shift. Oncologists must proactively use strategies like prophylactic antibiotics, a departure from managing typical chemotherapy-induced myelosuppression.

The efficacy of new KRAS inhibitors is set to fundamentally shift pancreatic cancer research. These agents are expected to become the new standard therapeutic backbone, meaning future clinical trials will likely test new drugs in combination with a RAS inhibitor, moving beyond chemotherapy-only combinations.

The combination of the KRAS G12C inhibitor Sotorasib with immunotherapy, a seemingly logical approach, has been abandoned. Clinical trials were closed due to unacceptable levels of hepatotoxicity (liver damage), particularly in patients who had recently received immunotherapy. This demonstrates an unexpected and clinically significant negative drug-drug interaction, serving as a cautionary tale for future combination studies.

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.